PubMed Health⌕ Search

Biomedical subjects

R B Conolly

Publications and source records attributed to R B Conolly.

At least 37 records · Page 2Linked to original sources
PubMed1997

Comparison of inhaled formaldehyde dosimetry predictions with DNA-protein cross-link measurements in the rat nasal passages.

Kimbell and coworkers (Toxicol, Appl. Pharmacol, 121, 253-263, 1993) developed a computational fluid dynamics (CFD) model of a F344 rat nasal passage to quantify local wall mass flux (uptake rate) of inhaled chemical. To simulate formaldehyde uptake, Kimbell et al. assumed that mass transfer of formaldehyde from the air into the nasal lining was fast and complete. This was approximated in the CFD model by setting the formaldehyde concentration at the airway walls to zero. Experimental confirmation of formaldehyde mass-flux predictions is desirable if the CFD model is to be used for predicting formaldehyde dosimetry. The purpose of this study was to see if the CFD model predictions of formaldehyde mass flux are consistent with laboratory data on formaldehyde dosimetry. In this study, a mathematical model of the nasal lining was modified to link CFD dosimetry predictions for inhaled formaldehyde with measured tissue disposition of inhaled gas. This model treats the nasal lining as a single, well-stirred compartment, accounts for formaldehyde reaction via saturable and first-order pathways, and allows comparison of model-predicted DNA-protein cross-links (DPX) with regional DPX measured in formaldehyde-exposed rats. Effective Michaelis-Menten kinetic parameters (Vmax = 3040 microM/min and Km = 59 microM) and a pseudo-first-order rate constant for elimination of formaldehyde by nonsaturable pathways (kf = 6 min-1) were estimated (fit) using an average mass flux derived from experimentally measured uptake of formaldehyde. DPX predictions obtained using the estimated kinetic parameters and linking the CFD model to the nasal-lining model compared well with experimentally measured DPX. The close correlation between predicted and measured DPX in the rat nasal passage supports the CFD model predictions of formaldehyde mass flux at the level of resolution provided by the experimental data.

Administration, Inhalation↗
PubMed1997

Hepatic foci in rats after diethylnitrosamine initiation and 2,3,7,8-tetrachlorodibenzo-p-dioxin promotion: evaluation of a quantitative two-cell model and of CYP 1A1/1A2 as a dosimeter.

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a potent hepatic tumor promoter in female rats. We used a quantitative, stochastic initiation-promotion model based on R. B. Conolly and J. S. Kimbell (Toxicol. Appl. Pharmacol. 124, 284-295, 1994) to analyze initiation-promotion results from a previously published study (H. C. Pitot et al., Carcinogenesis 8, 1491-1499, 1987) within the context of a negative selection model of tumor promotion. In this model, two types of initiated cells (called A and B cells) are produced by DEN initiation. Visually excellent correspondence between model predictions and data (i.e., foci/cm3 liver and percentage of liver occupied by foci) are obtained when TCDD is described as having dose-responsive effects on division and death (apoptotic) rates of these two cell types. For A cells, both the division and the death rates increase while the difference between division and apoptotic rates decreases. For B cells, the difference between division and apoptotic rates increases, primarily due to a decrease in the apoptotic rate. We also linked these alterations in cell kinetics to a pharmacokinetic model for TCDD incorporating a five subcompartment model of the liver acinus with induction of CYP1A1 and 1A2 genes in the subcompartments. Alterations in A cell kinetics correlate with effects of TCDD in the region most sensitive to induction (subcompartment 5-centrilobular region); B cell dynamics correlate with induction in subcompartments 3-5 (centrilobular and mid-zonal regions). In summary, these modeling exercises show that (1) the two-cell model, without presuming effects of TCDD on the mutation rate of normal hepatocytes, reproduces the data of Pitot et al. (1987) and (2) induction of CYP1A1/1A2 in different regions of the hepatic acinus can be used as a general correlate of these presumed changes in cell growth kinetics.

Animals↗
PubMed1997

Computer simulation of clonal growth cancer models. I. Parameter estimation using an iterative absolute bisection algorithm.

Quantitative models of the relationship between exposure to chemical carcinogens and carcinogenic response are useful for hypothesis evaluation and risk assessment. The degree to which such models accurately depict the underlying biology is often a function of the need for mathematical tractability. When closed-form expressions are used, the need for tractability may significantly limit their complexity. This problem can be minimized by using numerical computer simulation methods to solve the model, thereby allowing more complex and realistic descriptions of the biology to be used. Unfortunately, formal methods of parameter estimation for numerical models are not as well developed as they are for analytical models. In this report, we develop a formal parameter estimation routine and apply it to a numerical clonal growth simulation (CGS) model of the growth of preneoplastic lesions consisting of initiated cells. An iterative bisection algorithm was used to estimate parameters from time-course data on the number of initiated cells and the number of clones of these cells. The algorithm successfully estimated parameter values to give a best fit to the observed dataset and was robust vis-à-vis starting values of the parameters. Furthermore, the number of data points to which the model was fit, the number of stochastic repetitions and other variables were examined with respect to their effects on the parameter estimates. This algorithm facilitates the application of CGS models for hypothesis evaluation and risk assessment by ensuring uniformity and reproducibility of parameter estimates.

Algorithms↗
PubMed1996

A 90-day chloroform inhalation study in female and male B6C3F1 mice: implications for cancer risk assessment.

High doses of chloroform induced liver cancer in male and female B6C3F1 mice when administered by gavage, kidney cancer in male Osborne-Mendel rats when given by gavage or in the drinking water, and kidney cancer in male BDF1 mice when administered by inhalation. The weight of evidence indicates that chloroform is acting through a nongenotoxic-cytotoxic mode of action. The present study was designed to investigate the dose-response relationships for chloroform-induced lesions and regenerative cell proliferation in B6C3F1 mice as the basis for formulation of a biologically based risk assessment for inhaled chloroform. Different groups of female and male B6C3F1 mice were exposed to atmospheric concentrations of 0, 0.3, 2, 10, 30, and 90 ppm chloroform 6 hr/day, 7 days/week for exposure periods of 4 days or 3, 6, or 13 consecutive weeks. Some additional exposure groups were exposed for 5 days/week for 13 weeks or were exposed for 6 weeks and then examined at 13 weeks. Bromodeoxyuridine was administered via osmotic pumps implanted 3.5 days prior to necropsy, and the labeling index (LI, percentage of nuclei in S-phase) was evaluated immunohistochemically from histological sections. Complete necropsy and microscopic evaluation revealed treatment-induced dose- and time-dependent lesions only in the livers and nasal passage of the female and male mice and in the kidneys of the male mice. Large, sustained increases in the liver LI were seen in the 90-ppm groups at all time points. The female mice were most sensitive, with a no-observed-adverse-effect level (NOAEL) for induced hepatic cell proliferation of 10 ppm. The hepatic LI in the 5 days/week groups were about half of those seen in the 7 days/week groups and had returned to the normal baseline in the 6-week recovery groups. Induced renal histologic changes and regenerative cell proliferation were seen in the male mice at 30 and 90 ppm with 7 days/week exposures and also at 10 ppm with the 5 days/week regimen. Nasal lesions were transient and confined to mice exposed to 10, 30, or 90 ppm for 4 days. In a previous cancer bioassay, a gavage dose of 477 mg/kg/day produced a 95% liver tumor incidence in female B6C3F1 mice. This gavage dose is equivalent to a daily 6 hr/day inhalation exposure of approximately 80 ppm, based on the observed induced increases in the LI as an internal dosimeter. The United States Environmental Protection Agency currently uses the linearized multistage model applied to the mouse liver tumor data from the chloroform gavage study to estimate a virtually safe dose (VSD) as a one in a million increased lifetime risk of cancer. The resulting value is an airborne exposure concentration of 0.000008 ppm. Assuming that chloroform-induced female mouse liver cancer is secondary to events associated with necrosis and regenerative cell proliferation, then no increases in liver cancer in female mice would be predicted at the NOAEL of 10 ppm or below based on the results reported here. Applying an uncertainty factor of 1000 yields an estimate of a VSD at 0.01 ppm. This estimate relies on inhalation data and is more consistent with the mode of action of chloroform.

Administration, Inhalation↗
PubMed1996

DNA-protein cross-links (DPX) and cell proliferation in B6C3F1 mice but not Syrian golden hamsters exposed to dichloromethane: pharmacokinetics and risk assessment with DPX as dosimeter.

Dichloromethane (DCM) (methylene chloride; CH2Cl2) is metabolized via a glutathione S-transferase-mediated pathway to formaldehyde (HCHO), a mutagenic compound that could play a role in the carcinogenic effects of DCM observed in the liver and lungs of B6C3F1 mice at 2000 and 4000 ppm. Mice but not hamsters formed DNA-protein cross-links (DPX) in the liver at DCM concentrations ranging from approximately 500 to 4000 ppm. The formation of DPX was a nonlinear function of the airborne concentration of DCM. In addition, mice exposed to DCM (6 hr/day, 3 days) at concentrations ranging from approximately 1500 to 4000 ppm showed an increased rate of DNA synthesis in the lung indicating cell proliferation, but increased cell turnover was not detected in mouse lung at exposure concentrations of 150 or 500 ppm. Hamsters showed no evidence of cell proliferation in the lung at any concentration, and cell proliferation was not apparent in the livers of either mice or hamsters. An extended physiologically based pharmacokinetic (PBPK) model for DPX formation in mouse liver was developed, based on a published PBPK model for DCM (Andersen, M.E., Clewell, H.J., III, Gargas, M.L., Smith, F.A., and Reitz, R.H. (1987). Toxicol. Appl. Pharmacol. 87, 185-205). The extended PBPK model was fitted to the DPX data using the PBPK model-estimated area under the curve for DCM in mouse liver as the independent variable. Parameter estimates for HCHO disposition in the livers of mice exposed to dichloromethane were similar to previously published estimates for HCHO disposition in the nasal mucosa of rats exposed to formaldehyde. Using the extended PBPK model, estimates were made of the yields of DPX presumably formed in mouse liver at the DCM concentrations used in a bioassay (Mennear, J.H., McConnell, E.E., Huff, J.E., Renne, R.A., and Giddens, E. (1988). Ann. NY Acad. Sci. 534, 343-351). The tumor incidence data in mice were fitted to the DPX yields and to the airborne concentration of DCM as alternative measures of exposure using the linearized multistage (LMS) model. The two dose measures yielded similar maximum likelihood estimates for the cancer risk at concentrations from 10 to 100 ppm, but the upper 95% confidence limit on the risk was reduced by two orders of magnitude when DPX rather than the airborne concentration was used as the measure of exposure. The results demonstrate that an internal dosimeter such as DPX can markedly improve the precision of low-dose risk estimates, while having only a minor effect on the maximum likelihood estimates calculated with the LMS model.

Administration, Inhalation↗
PubMed1996

Apoptosis and cancer risk assessment.

Apoptosis is one form of physiological or active cell death. The balance between cell proliferation and cell death or apoptosis not only effects organ growth but also has a profound impact on the net increase and growth of initiated cells and preneoplastic and tumor cell populations. With respect to cancer development apoptosis is becoming widely recognized as being an innate tissue defense against carcinogens by inhibiting survival and controlling growth of precancerous cell populations and tumors at different stages of carcinogenesis. Experimental data on cell birth and cell death rates help identify the mode of action of a chemical and can be incorporated into biologically based cancer models. This article describes the quantitation and regulation of apoptosis in rodent liver and how loss of regulation can have a role in hepatocarcinogenesis. A biologically-based mouse liver cancer model is presented and utilized to describe how treatment related growth effects affect the process of carcinogenesis. Advantages and limitations of biologically based cancer models in cancer research and risk assessment are discussed.

Animals↗
PubMed1995

Cancer and non-cancer risk assessment: not so different if you consider mechanisms.

Default risk assessment procedures use threshold models for non-carcinogens and a non-threshold model for carcinogens. This a priori distinction reflects the fact that the default procedures do not consider mechanisms of action of specific chemicals. When mechanisms are considered, the distinction is not necessary. Starting with the premise that the goal of risk assessment is to identify actual risk for specific chemicals, three major, generic components of the overall mechanism translating exposure into a response of regulatory interest are identified. These are the specific mechanisms linking (1) exposure with dose to target tissue, (2) target tissue dose with short-term responses such as cytolethality or mutation, and (3) short-term responses with ensuing long-term responses such as cancer or cirrhosis. (Short-term responses may be regulatory end points of interest, or they may be intermediate steps on the way to longer-term sequelae). On-going research on formaldehyde and chloroform is described to illustrate how these three components of the overall mechanism can be examined experimentally and used in specific models. The impact of mechanism-based risk assessment on uncertainty is also considered. Uncertainty is a function of the extent to which the model used for risk assessment misspecifies the actual mechanism of action for the chemical in question. There is a trade-off between (a) mechanism-based models that may reduce uncertainty but are expensive and time-consuming to develop and (b) default models that are not chemical-specific but can be used with minimal data sets. Experience with mechanism-based risk assessment may allow modification of default procedures to minimize this trade-off. A future default procedure for carcinogen risk assessment might allow specification of mode of action. For example, while DNA reactive-carcinogens would still be assumed to have linear low-dose risk, carcinogens acting through purely cytotoxic mechanisms might be assumed to have sharply non-linear or even threshold dose-response curves.

Animals↗
PubMed1995

A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments.

The current standard approach for assessing carcinogenic potential is to conduct a near lifetime rodent pathology study with the high dose set to the maximum tolerated dose (MTD) of the test chemical. The linearized multistage model is then used as the default approach to estimate the potential human cancer risk at environmental elvels of the chemical. There is an increasing appreciation in the scientific and regulatory communities that chemical carcinogens differ dramatically in potency, exhibit a high degree of tissue and species specificity, and act through different modes of action. This paper advocates a decision tree strategy for classifying carcinogens that are acting primarily through genotoxic, cytotoxic, or mitogenic pathways. A primary concern is whether the chemical has direct genotoxic potential resulting from DNA reactivity or clastogenicity of the compound or its metabolite(s). Knowledge of the exposure-response curve for cytotoxicity is important because initiation and promotion events may occur secondary to a variety of associated activities such as regenerative cell proliferation. Mitogens indice direct stimulation of growth and may provide a selective growth advantage to spontaneously initiated precancerous cells. Of particular concern is the situation where pathological changes induced during the course of the treatment at high doses near the MTD are absent at lower, environmentally relevant, doses. If the tumor response is coincident with the preceding toxic response, it may not be justified to use the high-dose data in extrapolating to expected responses at low environmental exposures where no induced tissue abnormalities occur. Suggestions are presented for appropriate risk assessment approaches for different modes of action. Examples discussed are formaldehyde, a weakly genotoxic rodent nasal carcinogen; chloroform, a nongenotoxic-cytotoxic rodent liver and kidney carcinogen; and phenobarbital, a nongenotoxic-mitogenic rodent liver carcinogen.

Animals↗
PubMed1995

Development of a mechanism-based dosimetry model for 2,4,4-trimethyl-2-pentanol-induced alpha 2u-globulin nephropathy in male Fischer 344 rats.

A mechanism-based dosimetry model was developed to describe 2,4,4-trimethyl-2-pentanol (TMP-2-OH) dosimetry and renal alpha 2u-globulin (alpha 2u) nephropathy in the male Fischer 344 rat. Experimental data were collected to estimate the chemical-specific parameters (metabolic constants, tissue solubility, and oral absorption rate) necessary to describe TMP-2-OH dosimetry in male rats. The concentrations of alpha 2u and TMP-2-OH were measured in male rats up to 64 hr after a single oral dose of TMP-2-OH (6, 60, or 600 mg/kg). The model predicted the time course behavior of TMP-2-OH and alpha 2u in the kidney, but overestimated their renal concentrations by two or threefold. Simulations of renal alpha 2u concentration were sensitive to changes in TMP-2-OH-alpha 2u-binding affinity and degradation rate of the TMP-2-OH-protein complex. In contrast, simulation of the concentration of TMP-2-OH in the kidney was most sensitive to the amount of protein present. Oral absorption of TMP-2-OH was dose dependent. The model predicted that alpha 2u and TMP-2-OH concentration in the kidney is sensitive to changes in the rate of TMP-2-OH absorbed after oral administration. This model permitted a more rigorous evaluation than has previously been possible of the combination of protein characteristics and chemical dosimetry required for the accumulation of alpha 2u in the kidney of male rats. The behavior of the model is consistent with the qualitative aspects of the alpha 2u hypothesis. However, further characterization of alpha 2u distribution and renal hydrolysis will be required in order to fully characterize the hypothesis at the quantitative level.

Administration, Oral↗
PubMed1995

Development of a physiologically based pharmacokinetic model describing 2-methoxyacetic acid disposition in the pregnant mouse.

Using the potent developmental toxicant 2-methoxyethanol (2-ME) as a prototypical compound, a physiologically based pharmacokinetic (PBPK) model was developed to describe the disposition of its primary metabolite and proximate toxicant 2-methoxyacetic acid (2-MAA) in the pregnant CD-1 mouse. Data were collected during early, mid, and late organogenesis, specifically Gestation Days (GD) 8, 11, and 13 (GD 0 = plug-positive date). Pharmacokinetics and tissue partition coefficients for 2-MAA were determined in maternal plasma and conceptus on GD 8 and in maternal plasma, embryo, and extraembryonic/amniotic fluid (EAF) on GD 11 and 13. For simulation of GD 8 data, the conceptus was described as a single compartment, combining the yolk sac placenta, embryo, EAF, and decidua. For GD 11 and 13, the placenta, embryo, and EAF were explicitly described. Several hypotheses were tested for their ability to predict 2-MAA dosimetry. These hypotheses were encoded as alternative models having (a) blood flow-limited delivery of 2-MAA to model compartments, (b) pH trapping of ionized 2-MAA within compartments, (c) active transport of 2-MAA into compartments, and (d) reversible binding of 2-MAA within compartments. While the flow-limited description adequately predicted GD 8 dosimetry, the best simulations of the pharmacokinetic data collected on GD 11 and 13 were obtained with the active transport models. Since the mechanism by which 2-MAA accumulates into the embryo and EAF has not yet been elucidated, these mathematical descriptions are empirical. Further development of this PBPK model for 2-MAA in pregnant mice, in particular its scale-up to humans, will facilitate more realistic human risk assessments for the developmental toxicity of 2-ME and related compounds.

Acetates↗
PubMed1995

Physiologically based pharmacokinetic models applicable to organogenesis: extrapolation between species and potential use in prenatal toxicity risk assessments.

A physiologically based pharmacokinetic (PBPK) model describing the disposition of 2-methoxyacetic acid (2-MAA; the proximate toxicant derived from oxidation of the ethylene glycol ether, 2-methoxyethanol) was developed in pregnant rodents. This model was validated with pharmacokinetic (PK) data from dams and embryos during major organogenesis. A physiological model of human pregnancy was then combined with the PBPK model and linked to an empirical 2-MAA PK model with 2 maternal compartments and a single or multiple conceptus compartment, depending on the developmental stage. This approach is intended to allow more realistic human pregnancy risk assessments by refining the reference dose calculations via uncertainty factors. It will be possible to eliminate an uncertainty factor of 10 for interspecies extrapolations in the 2-methoxyethanol risk assessment if the PBPK model described here is used.

Acetates↗
PubMed1995

Biologically based dose response model for hepatic toxicity: a mechanistically based replacement for traditional estimates of noncancer risk.

Uncertainty in risk assessment can be reduced by increasing the use of relevant data specific to the particular xenobiotic and exposed organism. We describe the development of a preliminary, mechanism-based exposure response model for chloroform hepatotoxicity consistig of toxicokinetic (TK) and toxicodynamic (TD) submodels. The TK submodel is based on an existing physiologically based toxicokinetic (PBTK) model for chloroform. The TD submodel consists of an empirical function linking tissue dose, defined by the PBTK model, with hepatocyte killing and subsequent regenerative cellular replication. Chloroform-induced cell killing was inferred quantitatively from dose-response hepatic labelling index studies conducted in female B6C3F1 mice and male F344 rats. The overall model was scaled to humans by conventional scaling of the TK submodel and by using the TD submodel as is, i.e. as developed from the rodent data. The resulting human model was used to analyze a case of human poisoning which developed after repeated ingestion of large doses of cough syrup containing chloroform and alcohol. The model predicted the observed toxic response after the capacity for chloroform metabolism was increased by a factor of 3 from the value estimated using human liver microsomes. This is an acceptable adjustment of this parameter, given the uncertainty associated with the extrapolation from microsomes and the coexposure to alcohol. This preliminary result is encouraging, suggesting that the model, at its current stage of development, is able to approximate actual human risks of hepatotoxicity from chloroform exposure. The extensive use of data on chloroform TK and cytolethality-induced regenerative cellular replication for model development suggests that the model has reduced uncertainty relative to the current U.S. EPA oral reference dose (RfD) calculation for chloroform, which does not use any mechanistic or dose-response data.

Animals↗
PubMed1995

The role of regenerative cell proliferation in chloroform-induced cancer.

Chloroform produces cancer by a nongenotoxic-cytotoxic mode of action, with no increased cancer risk expected at noncytotoxic doses. The default risk assessment for inhaled chloroform relies on liver tumor incidence from a gavage study with female B6C3F1 mice and estimates a virtually safe dose (VSD) at an airborne concentration of 0.000008 ppm of chloroform. In contrast, a 1000-fold safety factor applied to the NOAEL for liver cytotoxicity from inhalation studies yields a VSD of 0.01 ppm. This estimate relies on inhalation data and is more consistent with the mode of action of chloroform.

Animals↗
PubMed1995

An improved approximation to the exact solution of the two-stage clonal growth model of cancer.

Multistage clonal growth models are of interest for cancer risk assessment because they can explicitly incorporate data on cell replication. Both approximate and exact formulations of the two stage growth model have been described. The exact solution considers the conditional probability of tumors arising in previously tumor-free animals; the approximate solution estimates total probability of tumor formation. The exact solution is much more computationally intensive when time-dependent cell growth parameters are included. The approximate solution deviates from the exact solution at high incidences and probabilities of tumor. This report describes a computationally tractable, 'improved approximation' to the exact solution. Our improved approximation includes a correction term to adjust the unconditional expectation of intermediate cells based on the time history of formation of intermediate cells by mutation of normal cells (recruitment) or by cell division in the intermediate cell population (expansion). The improved approximation provided a much better match to the exact solution than the approximate solution for a wide range of parameter values. The correction term also appears to provide insight into the biological factors that contribute to the variance of the expectation for the number of intermediate cells over time.

Algorithms↗
PubMed1994

Computer simulation of cell growth governed by stochastic processes: application to clonal growth cancer models.

Cancer is a multistage process in which cell proliferation determines the growth of cells within stages and is associated with the transition of cells from one stage to the next. The usual model for cancer risk assessment, the linearized multistage model, does not explicitly include cell proliferation. More realistic cancer models are needed to reduce uncertainty in cancer risk assessment and to provide basic insights into the quantitative roles of cell proliferation and mutation. This report describes a simulation model for the transition of cells from one stage to the next and for clonal growth within stages. The model is intended to facilitate the use of experimental data on cell replication and preneoplastic lesions in risk assessment. When a population of cells is small its growth may be governed by stochastic processes. Such a population may disappear by chance even when the probability of cell division on a given time interval exceeds the probability of cell death. Procedures for estimating cell proliferation and mutation parameters from data for use in risk assessment should account for this random aspect of growth. The present model describes cell growth governed by stochastic processes, is consistent with earlier analytical expressions for such growth (Dewanjii et al., Risk Anal. 9, 179, 1989), and is flexible with respect to time-dependent data. A data set for spontaneous basophilic clones in male F344 rats (Popp et al., Fundam. Appl. Toxicol. 5, 314, 1985) is analyzed and predictions are made for (a) the probability of mutation to the basophilic genotype per division of a normal hepatocyte (3.5 x 10(-8)), (b) number of basophilic clones too small to be detected, and (c) number of basophilic clones that disappear by chance. This work illustrates the potential of computer simulation for quantitative analysis of the roles of cell division, cell death, and mutation in cancer.

Animals↗
PubMed1994

Physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters.

Organophosphate (OP) exposure can be lethal at high doses while lower doses may impair performance of critical tasks. The ability to predict such effects for realistic exposure scenarios would greatly improve OP risk assessment. To this end, a physiologically based model for diisopropylfluorophosphate (DFP) pharmacokinetics and acetylcholinesterase (AChE) inhibition was developed. DFP tissue/blood partition coefficients, rates of DFP hydrolysis by esterases, and DFP-esterase bimolecular inhibition rate constants were determined in rat tissue homogenates. Other model parameters were scaled for rats and mice using standard allometric relationships. These DFP-specific parameter values were used with the model to simulate pharmacokinetic data from mice and rats. Literature data were used for model validation. DFP concentrations in mouse plasma and brain, as well as AChE inhibition and AChE resynthesis data, were successfully simulated for a single iv injection. Effects of repeated, subcutaneous DFP dosing on AChE activity in rat plasma and brain were also well simulated except for an apparent decrease in basal AChE activity in the brain which persisted 35 days after the last dose. The psychologically based pharmacokinetic (PBPK) model parameter values specific for DFP in humans, for example, tissue/blood partition coefficients, enzymatic and nonenzymatic DFP hydrolysis rates, and bimolecular inhibition rate constants for target enzymes were scaled from rodent data or obtained from the literature. Good agreement was obtained between model predictions and human exposure data on the inhibition of red blood cell AChE and plasma butyrylcholinesterase after an intramuscular injection of 33 micrograms/kg DFP and at 24 hr after acute doses of DFP (10-54 micrograms/kg), as well as for repeated DFP exposures.(ABSTRACT TRUNCATED AT 250 WORDS)

Acetylcholinesterase↗